Global Sucralfate Market Size By Type (Powder, Suspension), By Application (Tablet formulation, Liquid antacid formulation), By Region, And Segment Forecasts, 2023 to 2032

The Global Sucralfate Market was valued at USD 620 million in 2023 and is projected to reach USD 987 million by 2031, growing at a CAGR of 6.0% during the forecast period of 2023–2031. Sucralfate, a gastroprotective agent commonly used to treat ulcers and gastritis, has witnessed increasing demand due to the rising prevalence of gastrointestinal (GI) disorders globally. The market is also driven by its expanding use in hospital formularies, cost-effective nature, and growing awareness about non-systemic treatment options for acid-peptic disorders.

Drivers:

1. Rising Incidence of Gastrointestinal Disorders:

An increase in peptic ulcers, GERD, and stress ulcers—often attributed to changing lifestyles, diet, and stress—is propelling the need for sucralfate as a front-line treatment.

2. Growing Geriatric Population:

With aging comes a heightened susceptibility to GI issues, creating a consistent demand for gastroprotective drugs like sucralfate.

3. Increased Use in Hospital Settings:

Hospitals and clinics are increasingly adopting sucralfate due to its favorable safety profile, especially for patients at risk of drug interactions from systemic therapies.

Restraints:

1. Limited Efficacy Compared to Proton Pump Inhibitors (PPIs):

Sucralfate is often considered less effective than PPIs for certain conditions, limiting its adoption as a first-line therapy in some regions.

2. Availability of Generic Alternatives:

The widespread availability of generics creates pricing pressure, which can impact the revenue growth for branded formulations.

Opportunity:

1. Expansion in Emerging Markets:

Countries in Asia-Pacific and Latin America are witnessing increased investments in healthcare infrastructure, expanding access to prescription drugs like sucralfate.

2. Pediatric and Veterinary Applications:

R&D focused on extending the applications of sucralfate to pediatric and veterinary segments is opening new avenues for growth.

Market by System Type Insights:

By formulation, tablet form remains the dominant system type, accounting for the largest market share in 2023, owing to ease of administration and affordability. However, the suspension form is expected to grow significantly, particularly for patients with difficulty swallowing or requiring flexible dosing in hospitals.

Market by End-use Insights:

The hospital pharmacy segment led the market in 2023, supported by institutional prescriptions and use in intensive care settings for stress ulcer prophylaxis. The retail pharmacy segment is also witnessing substantial growth due to increased over-the-counter availability in several regions.

Market by Regional Insights:

North America accounted for the largest market share in 2023 due to the region's high prevalence of GI disorders and developed healthcare infrastructure. Asia-Pacific is projected to grow at the fastest pace, driven by increasing healthcare awareness, a large patient population, and improved access to medications in countries such as India and China.

Competitive Scenario:

Prominent players in the Global Sucralfate Market include AbbVie Inc., Teva Pharmaceutical Industries Ltd., Zydus Lifesciences, Mylan N.V., Cipla Ltd., Sanofi, Dr. Reddy's Laboratories, Sun Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals, and Aurobindo Pharma. These companies are engaging in product innovation, expanding manufacturing capabilities, and forming strategic partnerships to enhance their market presence.

Scope of Work – Global Sucralfate Market

Report Metric Details

Market Size (2023) USD 620 million

Projected Market Size (2031) USD 987 million

CAGR (2023–2031) 6.0%

Market Segments By System Type (Tablet, Suspension), By End-Use (Hospital Pharmacy, Retail Pharmacy), By Region

Growth Drivers Rising GI disorder prevalence, aging population, increasing hospital use

Opportunities Expansion in emerging markets, pediatric and veterinary applications

Key Market Developments:

2023: Glenmark Pharmaceuticals launched a flavored oral sucralfate suspension for pediatric use, enhancing palatability and compliance.

2024: Cipla Ltd. expanded its gastroenterology product portfolio by introducing sucralfate tablets in new packaging formats for better shelf life.

2025: Teva Pharmaceuticals entered a strategic supply agreement with major hospital chains in Latin America to distribute sucralfate across regional networks.

FAQs:

1) What is the current market size of the Global Sucralfate Market?

The Global Sucralfate Market was valued at USD 620 million in 2023.

2) What is the major growth driver of the Global Sucralfate Market?

The major growth driver is the rising prevalence of gastrointestinal disorders, particularly ulcers and GERD.

3) Which is the largest region during the forecast period in the Global Sucralfate Market?

North America holds the largest market share, while Asia-Pacific is projected to grow fastest during the forecast period.

4) Which segment accounted for the largest market share in the Global Sucralfate Market?

The tablet formulation segment held the largest market share in 2023.

5) Who are the key market players in the Global Sucralfate Market?

Key players include AbbVie, Teva Pharmaceuticals, Cipla, Zydus Lifesciences, Sun Pharma, and Sanofi.